**Editor**

Josef S Smolen

Associate Editors

Francis Berenbaum
Dimitrios Boumpas
Gerd Burmester
Mary Crow
Kimme Hyrich
Rik Lories
Iain McInnes
Thomas Pap
David Pisetsky
Désirée van der Heijde
Kazuhiko Yamamoto

Editorial office

Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WC1H 9JR, UK
T: +44 (0)20 3655 5889
E: ard@bmj.com
Twitter: @ARD_BMJ
ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)

Disclaimer: The Editor of *ARD* has been granted editorial freedom and *ARD* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *ARD* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *ARD* does not imply endorsement. Neither *EULAR* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *ARD* (except for liability which cannot be legally excluded).

Copyright: © 2022 BMJ Publishing Group Ltd and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced in any form without permission.

ARD is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases, ISSN 0003-4967 (USPS 2152) is published monthly by BMJ Publishing Group Ltd, BMA House, Tavistock Square, WC1H 9JR London. Airfreight and mailing in the USA by agent named World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Periodicals postage paid at Brooklyn, NY 11256. US Postmaster: Send address changes to Annals of the Rheumatic Diseases, World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Subscription records are maintained at BMA House, Tavistock Square, WC1H 9JR London. Air Business Ltd is acting as our mailing agent.

Editorial

- 451** What evidence is needed to demonstrate the beneficial effects of exercise for osteoarthritis?
M Kloppenburg, F Rannou, F Berenbaum

Review

- 454** Cutaneous signs and mechanisms of inflammasomopathies
C Borst, D Symmank, M Drach, W Weninger

Viewpoint

- 466** No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?
J Braun, R BM Landewé

Rheumatoid arthritis

- 469** Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study
E Nasonov, S Fatenejad, E Feist, M Ivanova, E Korneva, D G Krechikova, A L Maslyanskiy, M Samsonov, R Stoilov, E V Zonova, M Genovese

- 480** Key interactions in the trimolecular complex consisting of the rheumatoid arthritis-associated DRB1*04:01 molecule, the major glycosylated collagen II peptide and the T-cell receptor
C Ge, S Weisse, B Xu, D Dobritzsch, J Viljanen, J Kihlberg, N-N Do, N Schneider, H Lanig, R Holmdahl, H Burkhardt

Psoriatic arthritis

- 490** Dactylitis is an indicator of a more severe phenotype independently associated with greater SJC, CRP, ultrasound synovitis and erosive damage in DMARD-naïve early psoriatic arthritis
S Dubash, O A Alabas, X Michelena, L Garcia-Montoya, R J Wakefield, P S Helliwell, P Emery, D G McGonagle, A L Tan, H Marzo-Ortega

Systemic lupus erythematosus

- 496** Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis
D Jayne, B Rovin, E F Mysler, R A Furie, F A Houssiau, T Trasiéva, J Knagenhjelm, E Schwetje, Y L Chia, R Tummala, C Lindholm

Systemic sclerosis

- 507** Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (SclerID) questionnaire
M O Becker, R Dobrota, A Garaiman, R Debelak, K Fligelstone, A Tyrrell Kennedy, A Roennow, Y Allamore, P E Carreira, L Czirják, C P Denton, R Hesselstrand, G Sandqvist, O Kowal-Bielecka, C Bruni, M Matucci-Cerinic, C Mihai, A M Gheorghiu, U Mueller-Ladner, J Sexton, T K Kvien, T Heiberg, O Distler

- 516** Large-scale analysis of longitudinal skin gene expression in systemic sclerosis reveals relationships of immune cell and fibroblast activity with skin thickness and a trend towards normalisation over time
B Skaug, M A Lyons, W R Swindell, G A Salazar, M Wu, T M Tran, J Charles, C P Vershel, M D Mayes, S Assassi

Vasculitis

- 524** Blocking GM-CSF receptor α with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritis
M Corbera-Bellalta, R Alba-Rovira, S Muralidharan, G Espigol-Frigolé, R Ríos-Garcés, J Marco-Hernández, A Denuc, F Kamberovic, P Pérez-Galán, A Joseph, A D'Andrea, K Bondensgaard, M C Cid, J F Paolini

Osteoarthritis

- 537** Exercise and education versus saline injections for knee osteoarthritis: a randomised controlled equivalence trial
E Bandak, R Christensen, A Overgaard, L E Kristensen, K Ellegaard, J Guldberg-Møller, C Bartholdy, D J Hunter, R Altman, H Bliddal, M Henriksen

MORE CONTENTS ►

EDITOR'S CHOICE

This article has been chosen by the Editor to be of special interest or importance and is freely available online.



OPEN ACCESS

This article has been made freely available online under the BMJ Journals open access scheme.

See <http://authors.bmj.com/open-access/>

C O P E

Member since 2008
JM00004

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>




When you have finished
with this please recycle it

- 544** Digoxin targets low density lipoprotein receptor-related protein 4 and protects against osteoarthritis
K Wang, X Ding, N Jiang, C Zeng, J Wu, X Cai, A Hettinghouse, A Khleborodova, Z-N Lei, Z-S Chen, G Lei, C Liu


Crystal arthropathies

- 556** Impact of adiposity on risk of female gout among those genetically predisposed: sex-specific prospective cohort study findings over >32 years
N McCormick, C Yokose, N Lu, A D Joshi, G C Curhan, H K Choi

Epidemiology

- 564** Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong
 *X Li, X Tong, W W Y Yeung, P Kuan, S H H Yum, C S L Chui, F T T Lai, E Y F Wan, C K H Wong, E W Y Chan, C S Lau, I C K Wong*

- 569** Survival after COVID-19-associated organ failure among inpatients with systemic lupus erythematosus in France: a nationwide study
A Mageau, T Papo, S Ruckly, A Strukov, D van Gysel, K Sacre, J-F Timsit

- 575** BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus
 *Q Moyon, D Sterlin, M Miyara, F Anna, A Mathian, R Lhote, P Ghillani-Dalbin, P Breillat, S Mudumba, S de Alba, F Cohen-aubart, J Haroche, M Pha, T H D Boutin, H Chaieb, P M Flores, P Charneau, G Gorochov, Z Amoura*

- 584** Average corticosteroid dose and risk for HBV reactivation and hepatitis flare in patients with resolved hepatitis B infection
Z Zhong, W Liao, L Dai, X Feng, G Su, Y Gao, Q Wu, P Yang

Letters

- 592** Immunogenicity of the COVID-19 mRNA vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors
D Dimopoulou, G Vartzelis, F Dasoula, M Tsolia, D Marisi
- 593** Third COVID-19 vaccine dose with BNT162b2 in patients with ANCA-associated vasculitis
C Speer, M Töllner, L Benning, K Klein, M Bartenschlager, C Nussbag, F Kälble, P Reichel, P Schnitzler, M Zeier, C Morath, W H Schmitt, R Bergner, R Bartenschlager, M Schaefer

- 595** Herpes zoster reactivation after mRNA-1273 vaccination in patients with rheumatic diseases
T-J Lee, C-H Lu, S-C Hsieh

- 597** Hypoglycaemia following JAK inhibitor treatment in patients with diabetes
J A van Lint, F P A M van Hunsel, S W Tas, H E Vonkeman, F Hoentjen, M B A van Doorn, R C F Hebing, M T Nurmohamed, B J F van den Bemt, E P van Puijenbroek, N T Jessurun

- 599** Clinical characteristics of juvenile gout and treatment response to febuxostat
S Zheng, P Y Lee, Y Huang, W Deng, Z Huang, Q Huang, S Chen, T Li

Electronic pages

- e53** Autoantibodies and interstitial lung disease in rheumatoid arthritis: towards a 'mix-and-match' approach?
A Alunno, O Bistoni, A F Bonifacio, R Gerli

- e54** Response to: 'Autoantibodies and interstitial lung disease in rheumatoid arthritis: towards a 'mix-and-match' approach' by Alunno *et al*
R Castellanos-Moreira, S C Rodríguez-García, I Haro, R Sanmarti

- e55** Increasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritis
S Bugatti, L De Stefano, E G Favalli, R Caporali, C Montecucco

- e56** Response to: 'Increasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritis' by Bugatti *et al*
P Studenic, D T Felson, M de Wit, J S Smolen, D Aletaha

- e57** Withdrawal of low-dose prednisone in inactive SLE patients: Is there another alternative?
J M Sabio

- e58** Response to: 'Withdrawal of low-dose prednisone in inactive SLE patients: is there another alternative?' by Sabio
A Mathian, M Pha, Z Amoura

- e59** External validation of EULAR/ACR classification criteria for idiopathic inflammatory myopathies
Q Luu, J Day, A Hall, V Limaye, G Major

- e60** Response to: 'External validation of EULAR/ACR classification criteria for idiopathic inflammatory myopathies' by Luu *et al*
M Jinnin, A Ohta, H Kohsaka
- e61** Successful treatment of plasma exchange for refractory systemic juvenile idiopathic arthritis complicated with macrophage activation syndrome and severe lung disease
S Sato, T Hosokawa, H Kawashima
- e62** Response to: 'Successful treatment of plasma exchange for refractory systemic juvenile idiopathic arthritis complicated with macrophage activation syndrome and severe lung disease' by Sato *et al*
V E Saper, G Chen, R P Guillerman, P Khatri, R Q Cron, E D Mellins
- e63** Is non-industrial society undergoing an energy balance transition predisposed to accumulate abdominal adipose tissue and susceptible to knee osteoarthritis?
Y Yu, S Lu, J Xu
- e64** Response to: 'Is non-industrial society undergoing an energy balance transition predisposed to accumulate abdominal adipose tissue and susceptible to knee osteoarthritis?' by Yu *et al*
I J Wallace, D T Felson, S Worthington, D E Lieberman
- e65** Use of tanezumab for patients with hip and knee osteoarthritis with reference to a randomised clinical trial by Berenbaum and colleagues
D Riddle, R Perera
- e66** Response to: 'Use of tanezumab for patients with hip and knee osteoarthritis with reference to a randomised clinical trial by Berenbaum and colleagues' by Riddle and Perera
F Berenbaum, F J Blanco, A Guermazi, K Miki, T Yamabe, L Viktrup, R Junor, W Carey, M T Brown, C R West, K M Verburg
- e67** JAK inhibitors as promising agents for refractory Takayasu arteritis
R Watanabe
- e68** Response to: 'JAK inhibitors as promising agents for refractory Takayasu arteritis' by Watanabe
S Tanimura, H Nakamura, T Horia